» Authors » Gary P Watters

Gary P Watters

Explore the profile of Gary P Watters including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 46
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Makwana O, Smith G, Flockton H, Watters G, Lowe F, Breheny D
Sci Rep . 2021 Feb; 11(1):4747. PMID: 33637800
Atherosclerosis is a complex process involving progressive pathological events, including monocyte adhesion to the luminal endothelial surface. We have developed a functional in vitro adhesion assay using BioFlux microfluidic technology...
2.
Makwana O, Flockton H, Smith G, Watters G, Nisar R, Fields W
Toxicol In Vitro . 2019 Mar; 58:239-244. PMID: 30885593
Chronic exposure to cigarette smoke can lead to endothelial dysfunction and potentially endothelial cell death. Here, we exposed Human Aortic Endothelial Cells (HAECs) to whole smoke conditioned media (WSCM) over...
3.
Makwana O, Flockton H, Watters G, Nisar R, Smith G, Fields W, et al.
Altern Lab Anim . 2017 Oct; 45(4):177-190. PMID: 28994298
Although chronic progressive cardiovascular diseases such as atherosclerosis are often challenging to fully model in vitro, it has been shown that certain in vitro methods can effectively evaluate some aspects...
4.
Cowell I, Papageorgiou N, Padget K, Watters G, Austin C
Nucleus . 2011 Jun; 2(1):61-71. PMID: 21647300
The genome is organized into large scale structures in the interphase nucleus. Pericentromeric heterochromatin represents one such compartment characterized by histones H3 and H4 tri-methylated at K9 and K20 respectively...
5.
Sunter N, Cowell I, Willmore E, Watters G, Austin C
J Nucleic Acids . 2010 Sep; 2010. PMID: 20847952
The role of topoisomerase IIβ was investigated in cell lines exposed to two DNA damaging agents, ionising radiation (IR) or etoposide, a drug which acts on topoisomerase II. The appearance...
6.
Leontiou C, Watters G, Gilroy K, Heslop P, Cowell I, Craig K, et al.
Mol Pharmacol . 2007 Jan; 71(4):1006-14. PMID: 17209120
Type II DNA topoisomerases are targets of acridine drugs. Nine mutations conferring resistance to acridines were obtained by forced molecular evolution, using methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide (mAMSA), methyl N-(4'-(9-acridinylamino)-2-methoxy-phenyl) carbamate...